ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Parmax Pharma Ltd filed its quarterly shareholding pattern under Regulation 31. The disclosure reflects changes in promoter status following a previously concluded open offer.
Parmax Pharma Ltd will hold its 32nd Annual General Meeting on September 29, 2026. The meeting will address the adoption of financial statements and director appointments.
Parmax Pharma's promoters acquired shares via preferential allotment. This filing discloses the acquisition of equity stakes by eleven promoter-related entities.
Promoter group members Dhiren Shah and Sunil Shah acquired 22,80,444 equity shares in Parmax Pharma Ltd. The acquisition occurred via a preferential allotment on August 29, 2026.
Parmax Pharma Ltd reported revenue from operations of ₹8.2 Cr (+331.6% YoY) and net profit of ₹2.2 Cr for Q1 FY27.